• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Second-Generation Antipsychotics Do Not Raise Risk of Major Malformations

Second-Generation Antipsychotics Do Not Raise Risk of Major Malformations

May 1, 2016
Bret A. Moore, PsyD, ABPP
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
bret-a-moore-psyd-abppBret A. Moore, PsyD, ABPP Board-Certified Clinical Psychologist, San Antonio, TX Dr. Moore has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Subject: (Cohen L et al, JAMA Psychiatry 2016;173:263–270)

Short Description: Second-generation antipsychotics (SGA) are used for a variety of psychiatric conditions, but even though they’ve been around for 20 years, we know little about what impact they have on the developing fetus. These medications are widely considered to be relatively safe during pregnancy, but this assumption is based on scant evidence. In this paper, researchers tapped into the Massachusetts General Hospital (MGH) National Pregnancy Registry of Atypical Antipsychotics and reported some reassuring results.

Over a six-year period, 214 women between the ages of 18 and 45 who had been exposed to an SGA during their first trimester were enrolled. These women were compared to a control group of 89 women who had a psychiatric illness during pregnancy, and who were treated with psychiatric medications but who were not exposed to an SGA. The women were interviewed at three time points: time of enrollment in the registry, 7 months pregnant, and 3 months post-partum. Medical records were also reviewed. There were a few differences between the two groups: notably 24% of SGA-exposed women smoked, compared to only 10% of women in the control group.

SGA-exposed women were also twice as likely to also be exposed to an anticonvulsant (40% vs 19%). Interestingly, the majority of women (about 60%) in both groups had a primary diagnosis of bipolar disorder, and only a small proportion (about 2%) carried a primary diagnosis of schizophrenia.

In the exposed group, the risk of developing a serious malformation was 1.4% (3 of 214 births); in the unexposed group, the risk was 1.1% (1 of 89 births). The researchers concluded that SGAs are unlikely to be teratogenic, but that the study sample is too small to reach a definite conclusion. They point out that the MGH registry continues to collect data on this issue, and that as the sample size increases, they will likely be able to estimate the risk with more precision.

TCPR’s Take: SGAs probably do not increase the risk of serious fetal malformations, which is reassuring. It’s important to note that the study did not report on less serious effects, such as higher birthweight, neonatal withdrawal, or even gestational diabetes. Prior studies of SGAs have shown possible associations with these outcomes, so counseling pregnant women about these meds remains complicated.
General Psychiatry
KEYWORDS antipsychotics psychopharmacology_tips research-update
Bret a moore psyd abpp
Bret A. Moore, PsyD, ABPP

Extended-Release Guanfacine Improves ADHD Symptoms in Autism

More from this author
www.thecarlatreport.com
Issue Date: May 1, 2016
SUBSCRIBE NOW
Table Of Contents
Take The CME Test For Correctional Psychiatry, TCPR, May 2016
Correctional Psychiatry: Salary and Benefits Are Generous
Second-Generation Antipsychotics Do Not Raise Risk of Major Malformations
Ongoing ECT Does Not Equal Ongoing Cognitive Problems
The Experience of Correctional Psychiatry
Psychopharmacology in Jails: An Introduction
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.